MAPK7 and prostate carcinoma: Indeed, nuclear ERK5 correlates with poor prognosis in aggressive prostatic carcinoma [21,25] and in hepatocellular carcinoma [19] and also confers resistance to TRAIL-induced apoptosis in breast cancer models [26].